A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Amgen 509 20180146 Prostate Cancer Study
Description
This study is being done to learn more about the drug; AMG 509 (xaluritamig) when used alone or in combination with either abiraterone or enzalutamide in men the metastatic prostate cancer. Participants will be in the study for 3 yrs. The study plans to enroll approximately 470 participants.
Protocol#: AMGEN-509-20180146
Study Information
Age Group: Adults
Participating Sites: Sanford Sioux Falls Region
Scope:
Phase: I
Participating Sites: Sanford Sioux Falls Region
Scope:
Phase: I
Principal Investigator(s)
Christopher Sumey
Department
Management Group:
Genitourinary - Oncology
NCT:
NCT04221542
Contact Us
For more information on clinical trials at Sanford Health, call one of our regional clinical research offices:
Sanford Sioux Falls Region: (605) 328-1368